Drugs / Egg-Derived Trivalent Subunit Influenza Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00310804 Comparator | Sep → Oct 2005 | influenza | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT00492063 Comparator | Sep → Dec 2004 | influenza | Novartis Vaccines | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Egg-derived trivalent subunit influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492063 ↗ |
| Known as | TIV | “Egg-derived trivalent subunit influenza vaccine (TIV)” NCT00492063 ↗1“Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)” NCT00310804 ↗ |
| Modality | Vaccine | “egg-derived subunit influenza vaccine” NCT00310804 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT00310804 ↗ |